HELP     Sign In
Search

Relevance to Autism

Studies have found rare single gene variations in the NLGN3 gene in autism. However, other studies claimed to find no rare variations in the NLGN3 gene in autism patients, although one of these found several silent variations. One study (Ylisaukko-oja et al., 2005) found a genetic association between an NLGN3 variant and autism in a sample of Finnish autism families, and another study (Yu et al., 2011) found a genetic association between an NLGN3 variant and autism in the Chinese Han population.

Molecular Function

This gene encodes a member of a family of neuronal cell-adhesion proteins located at the postsynaptic side of the synapse. Members of this family may act as splice site-specific ligands for beta-neurexins and may be involved in the formation and remodeling of central nervous system synapses.

External Links

        

References

Type
Title
Type of Disorder
Associated Disorders
Author, Year
Primary
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism.
ASD
Positive Association
A sex-specific association of common variants of neuroligin genes (NLGN3 and NLGN4X) with autism spectrum disorders in a Chinese Han cohort.
ASD
Positive Association
Analysis of four neuroligin genes as candidates for autism.
ASD
Negative Association
No evidence for involvement of genetic variants in the X-linked neuroligin genes NLGN3 and NLGN4X in probands with autism spectrum disorder on high functioning level.
ASD
Negative Association
Absence of coding mutations in the X-linked genes neuroligin 3 and neuroligin 4 in individuals with autism from the IMGSAC collection.
ASD
Negative Association
NLGN3/NLGN4 gene mutations are not responsible for autism in the Quebec population.
ASD
Negative Association
Mutation screening of X-chromosomal neuroligin genes: no mutations in 196 autism probands.
ASD
Negative association
Variations analysis of NLGN3 and NLGN4X gene in Chinese autism patients.
ASD
Negative association
Lack of association between NLGN3, NLGN4, SHANK2 and SHANK3 gene variants and autism spectrum disorder in a Chinese population.
ASD
Support
Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders.
ASD, SCZ
Support
Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing.
ASD
Support
Using whole-exome sequencing to identify inherited causes of autism.
ASD
Support
Identification of rare X-linked neuroligin variants by massively parallel sequencing in males with autism spectrum disorder.
ASD
Support
Identification of Four Novel Synonymous Substitutions in the X-Linked Genes Neuroligin 3 and Neuroligin 4X in Japanese Patients with Autistic Spectrum Disorder.
ASD
Support
Large-scale discovery of novel genetic causes of developmental disorders.
Specific learning disability
Support
Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing.
ID
Recent recommendation
Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors.
Recent Recommendation
A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice.
Recent Recommendation
Autism-related neuroligin-3 mutation alters social behavior and spatial learning.
Recent Recommendation
A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein family.
Recent Recommendation
Developmental regulation of GABAergic signalling in the hippocampus of neuroligin 3 R451C knock-in mice: an animal model of Autism.
Recent Recommendation
Expression patterns of neurexin-1 and neuroligins in brain and retina of the chick embryo: Neuroligin-3 is absent in retina.
Recent Recommendation
Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling.
Recent Recommendation
The Arg473Cys-neuroligin-1 mutation modulates NMDA mediated synaptic transmission and receptor distribution in hippocampal neurons.
Recent Recommendation
Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function.
Recent Recommendation
Neuroligin trafficking deficiencies arising from mutations in the alpha/beta-hydrolase fold protein family.
Recent Recommendation
Integrated systems analysis reveals a molecular network underlying autism spectrum disorders.
ASD
Recent Recommendation
Differential expression of neuroligin genes in the nervous system of zebrafish.

Rare

Variant ID
Variant Type
Allele Change
Residue Change
Inheritance Pattern
Inheritance Association
Family Type
Author, Year
 GEN171R001 
 missense_variant 
 c.1351C>T 
 p.Arg451Cys 
 Familial 
 Maternal 
 Multiplex 
 GEN171R002 
 synonymous_variant 
 A>G 
 p.(=) 
  
  
  
 GEN171R003 
 synonymous_variant 
 C>G 
 p.(=) 
  
  
  
 GEN171R004 
 synonymous_variant 
 G>A 
 p.(=) 
  
  
  
 GEN171R005 
 synonymous_variant 
 G>A 
 p.(=) 
  
  
  
 GEN171R006 
 synonymous_variant 
 G>A 
 p.(=) 
  
  
  
 GEN171R007 
 synonymous_variant 
 G>A 
 p.(=) 
  
  
  
 GEN171R008 
 synonymous_variant 
 G>A 
 p.(=) 
  
  
  
 GEN171R009 
 missense_variant 
 c.2189G>A 
 p.Thr632Ala 
 Familial 
 Maternal 
 Multiplex 
 GEN171R010 
 synonymous_variant 
 c.222C>T 
 p.(=) 
 Familial 
  
 Multiplex 
 GEN171R011 
 intron_variant 
 c.727+47G>C 
  
 Unknown 
  
 Unknown 
 GEN171R012 
 synonymous_variant 
 c.1698G>A 
 p.(=) 
 Unknown 
  
 Unknown 
 GEN171R013 
 intron_variant 
  
  
 Unknown 
  
 Multiplex 
 GEN171R014 
 intron_variant 
  
  
 Unknown 
  
 Multiplex 
 GEN171R015 
 intron_variant 
  
  
 Unknown 
  
 Multiplex 
 GEN171R016 
 intron_variant 
  
  
 Unknown 
  
 Multiplex 
 GEN171R017 
 3_prime_UTR_variant 
  
  
 Familial 
 Maternal 
 Multiplex 
 GEN171R018 
 missense_variant 
 c.962T>C 
 p.Val321Ala 
 Familial 
 Maternal 
 Simplex 
 GEN171R019 
 missense_variant 
 c.916G>A 
 p.Val306Met 
 Familial 
 Maternal 
 Simplex 
 GEN171R020 
 frameshift_variant 
 TC>T 
  
 Unknown 
  
 Unknown 
 GEN171R021 
 missense_variant 
 c.1276G>A 
 p.Gly426Ser 
 De novo 
  
 Simplex 
 GEN171R022 
 missense_variant 
 c.1954A>G 
 p.Thr652Ala 
 Unknown 
  
 Unknown 
 GEN171R023 
 stop_gained 
 G>A 
  
 Familial 
 Maternal 
 Simplex 
 GEN171R024 
 missense_variant 
 c.1849C>T 
 p.Arg617Trp 
 Familial 
 Maternal 
 Extended multiplex 

Common

Variant ID
Polymorphism
SNP ID
Allele Change
Residue Change
Population Origin
Population Stage
Author, Year
 GEN171C001 
 intron_variant 
 rs11795613 
 c.-200-72A>G;c.-272A>G;c.-38-585A>G;c.47-72A>G;c.- 
 G/A 
 Chinese Han 
 Discovery 
 GEN171C002 
 intron_variant 
 rs4844285 
 c.457+2188G>A;c.517+1489G>A;c.106+2188G>A;c.328+14 
 A to G 
 Chinese Han 
 Discovery 
 GEN171C003 
 intron_variant 
 rs4844286 
 c.458-3490T>G;c.458-1753T>G;c.518-1753T>G;c.107-17 
 G to T 
 Chinese Han 
 Discovery 
 GEN171C004 
 intron_variant 
 rs5981079 
 c.458-2809T>C;c.458-1072T>C;c.518-1072T>C;c.107-10 
 C to T 
 Chinese Han 
 Discovery 
 GEN171C005 
 intron_variant 
 rs7051529 
 c.458-860A>G;c.517+818A>G;c.577+818A>G;c.166+818A> 
 G/A 
 Chinese Han 
 Discovery 



Model Summary

Mutant mice display impaired social interactions; increase in inhibitory synaptic transmission

External Links

AllenBrainAtlas   MGI Logo  Entrez Gene

References

Type
Title
Author, Year
Primary
A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice.
Additional
Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit.
Additional
Minimal aberrant behavioral phenotypes of neuroligin-3 R451C knockin mice.
Additional
Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function.
Additional
Developmental regulation of GABAergic signalling in the hippocampus of neuroligin 3 R451C knock-in mice: an animal model of Autism.
Additional
Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors.
Additional
Enhanced synapse remodelling as a common phenotype in mouse models of autism.

NLGN3_1_KI_R451C

Model Type: Genetic
Model Genotype: Hemizygous males
Mutation: Exon 7 carrying coding mutation (R451C) replaced the wild type exon 7 using a neo cassette as a selectable marker and flanked by loxP sites
Allele Type: Targeted (knock-in)
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: 129S1/Sv * 129X1/SvJ * C57BL/6
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

NLGN3_2_KO

Model Type: Genetic
Model Genotype: Hemizygous males
Mutation: Exons 2 and 3 flanked by loxP sites, then removed by cre-mediated recombination
Allele Type: Targeted (knock-out)
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: 129S1/Sv * 129X1/SvJ * C57BL/6
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

NLGN3_4_KO

Model Type: Genetic
Model Genotype: Hemizygous males
Mutation: Exon sequence covering the translational start site and 574 bp of 5' coding sequence targeted for deletion by homologous recombination
Allele Type: Targeted (knock-out)
Strain of Origin: Not Specified
Genetic Background: C57Bl/6NCrl
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: 16982420

NLGN3_3_KI_R451C

Model Type: Genetic
Model Genotype: Hemizygous males, homozygous females
Mutation: A BAC targeting vector with the mutation of CGT (arginine451) to TGC (cysteine451) in exon 6 replaced the wild-type sequence.
Allele Type: Targeted (knock-in)
Strain of Origin: Not Specified
Genetic Background: C57Bl/6
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

NLGN3_10_cKO_D1-Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exons 2 and 3 flanked by loxP sites, D1-Cre transgene
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_11_cKO_A2a-Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exons 2 and 3 flanked by loxP sites, A2a transgene
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_12_KI_R451C_D1-Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exon 7 carrying coding mutation (R451C) replaced the wild type exon 7 using a neo cassette as a selectable marker and flanked by loxP sites, D1-Cre transgene
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_1_KI_R451C

NLGN3_13_cKO_DS_Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exons 2 and 3 flanked by loxP sites, Cre transgene injection in dorsal striatum
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_14_cKO_NAc_Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exons 2 and 3 flanked by loxP sites, Cre transgene injection in nucleus accumbens
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_5_KO

Model Type: Genetic
Model Genotype: Hemizygous males
Mutation: Exons 2 and 3 flanked by loxP sites, then removed by cre-mediated recombination
Allele Type: Targeted (knock-out)
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_6_KI_R451C

Model Type: Genetic
Model Genotype: Hemizygous males
Mutation: Exon 7 carrying coding mutation (R451C) replaced the wild type exon 7 using a neo cassette as a selectable marker and flanked by loxP sites
Allele Type: Targeted (knock-in)
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_1_KI_R451C

NLGN3_7_cKO_Nestin-Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exons 2 and 3 flanked by loxP sites, Nestin-Cre transgene
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_8_cKO_L7-Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exons 2 and 3 flanked by loxP sites, L7-Cre transgene
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_9_cKO_PV-Cre

Model Type: Genetic
Model Genotype: Other
Mutation: Exons 2 and 3 flanked by loxP sites, PV-Cre transgene
Allele Type: Targeted (knock-out); transgenic
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: C57Bl/6J
ES Cell Line: R1
Mutant ES Cell Line: Not Specified
Model Source: NLGN3_2_KO

NLGN3_1_KI_R451C_GEPH-GFP

Model Type: Genetic
Model Genotype: Hemizygous males
Mutation: The progenitor cells for layer 2/3 neurons in the somatosensory cortex and anterior frontal cortex of NLGN3_1_KI_R451C mice were transfected using in utero electroporation to label excitatory synapses. E15.5 timed pregnant mice were deeply anaesthetized, their uterine horns were exposed and approximately 1ul of DNA mixture, containing DsRed2 plasmid (1ug/ul) and Gephyrin-GFP plasmid (1-2ug/ul), was pressure injected into the lateral ventricle of each embryo through a micropipette. Electric pulse
Allele Type: Targeted (knock-in)
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: 129S1/Sv * 129X1/SvJ * C57BL/6
ES Cell Line: R1
Mutant ES Cell Line:
Model Source:

NLGN3_1_KI_R451C_PSD95-GFP

Model Type: Genetic
Model Genotype: Hemizygous males
Mutation: The progenitor cells for layer 2/3 neurons in the somatosensory cortex and anterior frontal cortex of NLGN3_1_KI_R451C mice were transfected using in utero electroporation to label excitatory synapses. E15.5 timed pregnant mice were deeply anaesthetized, their uterine horns were exposed and approximately 1ul of DNA mixture, containing DsRed2 plasmid (1ug/ul) and PSD-95-GFP plasmid (1-2ug/ul), was pressure injected into the lateral ventricle of each embryo through a micropipette. Electric pulses
Allele Type: Targeted (knock-in)
Strain of Origin: (129X1/SvJ x 129S1/Sv)F1-Kitl+
Genetic Background: 129S1/Sv * 129X1/SvJ * C57BL/6
ES Cell Line: R1
Mutant ES Cell Line:
Model Source:

NLGN3_1_KI_R451C

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor coordination and balance4
Increased
Description: Normal initial coordination with increased learning rate, compared to male littermate controls
Exp Paradigm: Accelerating rotarod, nine trials 4 to 40 rpm in 300 s
 Accelerating rotarod test
 6 weeks
Synapse density: Inhibitory1
Increased
Description: Increased density of inhibitory synapse protein markers: VGAT and gephyrin
Exp Paradigm: Immunohistochemistry; Fluorescence microscopy
 Immunohistochemistry; Fluorescence microscopy
 3 months
Hippocampal morphology2
Increased
Description: Increased dendritic branching of pyramidal neurons in stratum radiatum, compared to wild type, but No Change in stratum lacunosum or stratum moleculare
Exp Paradigm: Sholl analysis
 Sholl analysis
 Unreported
Synaptic morphology2
Decreased
Description: Decreased spine area, bouton area and number of vesicles per bouton, compared to wild type
Exp Paradigm: Electron microscopy analysis
 Electron microscopy
 Unreported
Intrinsic bursting events or spikes in cortical neurons3
Increased
Description: Increased spontaneous giant depolarizing potentials indicated by shorter cumulative inter-event-interval and higher cumulative probability in CA3 region of hippocampus, compared to wild type
Exp Paradigm: Whole-cell voltage-clamp recordings from CA3 region of hippocampus
 Whole-cell patch clamp
 P4-P9
Neurotransmitter release3
Increased
Description: Increased GABA transient in synaptic cleft indicated by decreased reduction of mGPSCs amplitude after bath application of TPMPA, compared to wild type
Exp Paradigm: Whole-cell voltage-clamp recordings of mGPSCs with GABAa competitive blocker
 Whole-cell patch clamp
 P11-P15
Spontaneous post synaptic events3
Increased
Description: Increased frequency of spontaneous mini GABA postsynaptic current events but No Change in amplitude, compared to wild type
Exp Paradigm: Whole-cell voltage-clamp recordings
 Whole-cell patch clamp
 P27-P35
Spontaneous post synaptic events: excitatory currents2
Increased
Description: Increased frequency of spontaneous mEPSCs in hippocampus, compared to wild type
Exp Paradigm: Whole cell patch-clamp recordings
 Whole-cell patch clamp
 Unreported
Spontaneous post synaptic events: inhibitory currents1
Increased
Description: Increased frequency of spontaneous inhibitory mini events but No Change in amplitude
Exp Paradigm: Whole cell patch-clamp recordings in layer 2-3 of somtosensory cortex
 Whole-cell patch clamp
 Unreported
Synaptic neuroreceptor ratio (NMDAR/AMPAR) dependent transmission2
Increased
Description: Increased ratio of NMDA/AMPA-mediated transmission in hippocampus, compared to wild type
Exp Paradigm: Whole cell patch-clamp recordings
 Whole-cell patch clamp
 Unreported
Synaptic transmission: excitatory2
Increased
Description: Increased fEPSP, compared to wild type
Exp Paradigm: Field potential recordings: slope of EPSP by range of stimulus (input/ output relationship)
 Field potential recordings: slope of EPSP by range of stimulus (input/ output relationship)
 Unreported
Synaptic transmission: inhibitory3
Abnormal
Description: Faster decay time of miniature GABAergic events, but No Change in rise time, compared to wild type
Exp Paradigm: Whole-cell voltage-clamp recordings of mGPSCs with GABAa competitive blocker
 Whole-cell patch clamp
 P9-P11
Neuronal ion channel activity2
Increased
Description: Increased decay time constant or NMDAR-mediated response, compared to wild type
Exp Paradigm: Whole cell patch-clamp recordings
 Whole-cell patch clamp
 Unreported
Spontaneous post synaptic events3
Increased
Description: Increased frequency of spontaneous mini GABA postsynaptic current events but No Change in amplitude, compared to wild type
Exp Paradigm: Whole-cell voltage-clamp recordings
 Whole-cell patch clamp
 P11-P15
Spontaneous post synaptic events3
Increased
Description: Increased frequency of spontaneous mini GABA postsynaptic current events but No Change in amplitude, compared to wild type
Exp Paradigm: Whole-cell voltage-clamp recordings
 Whole-cell patch clamp
 P4-P9
Spontaneous post synaptic events: excitatory currents3
Increased
Description: Increased frequency of spontaneous mini AMPA postsynaptic current events but No Change in amplitude, compared to wild type
Exp Paradigm: Whole-cell voltage-clamp recordings
 Whole-cell patch clamp
 P27-P35
Spontaneous post synaptic events: inhibitory currents2
Increased
Description: Increased frequency of spontaneous mIPSCs in somatosensory cortex, compared to wild type
Exp Paradigm: Whole cell patch-clamp recordings
 Whole-cell patch clamp
 Unreported
Synaptic plasticity: hippocampal LTP2
Increased
Description: Increased fEPSP slope 55-60 minutes after tetanic stimulation, compared to wild type
Exp Paradigm: Field potential recordings; Long-term potentiation three 100-Hz, 1-s stimuli
 Field potential recordings; Long term potentiation (LTP)
 Unreported
Synaptic transmission: excitatory2
Abnormal
Description: Increased sensitivity to ifenprodil, NR1/NR2B heterotetrameric-selective antagonist, compared to wild type
Exp Paradigm: Field potential recordings
 Field potential recordings
 Unreported
Synaptic transmission: inhibitory1
Increased
Description: Increased amplitude of evoked inhibitory response
Exp Paradigm: Whole cell patch-clamp recordings in layer 2-3 of somtosensory cortex
 Whole-cell patch clamp
 Unreported
Social interaction2
Decreased
Description: Decreased exploration of social target, compared to wild type
Exp Paradigm: Caged adult social interaction test
 Reciprocal social interaction test: confined stimulus mouse
 Unreported
Social memory2
Decreased
Description: Decreased preference for novel social target, compared to wild type
Exp Paradigm: Three-chamber social approach test: social novelty
 Three-chamber social approach test: social novelty
 Unreported
Social interaction1
Decreased
Description: Reduced social approach and preference for social interaction
Exp Paradigm: Social Interaction
 Reciprocal social interaction test: juvenile play
 2-4 months
Spatial learning1
Increased
Description: Enhanced spatial learning
Exp Paradigm: Morris water maze test
 Morris water maze test
 2-4 months
Protein expression level evidence1
Decreased
Description: Decreased expression of NL1 protein
Exp Paradigm: Western blot
 Western blot
 3 months
Protein expression level evidence1
Increased
Description: Increased expression of inhibitory synapse protein markers: VGAT and gephyrin
Exp Paradigm: Western blot
 Western blot
 3 months
Targeted protein expression2
Decreased
Description: Decrease in level of NL3, compared to wild type, compared to wild type
Exp Paradigm: Western blot
 Western blot
 Unreported
Protein expression level evidence2
Increased
Description: Increase level of NR2B, NR2A subunits, compared to wild type
Exp Paradigm: Western blot
 Western blot
 Unreported
Protein expression level evidence2
Increased
Description: Increased level of excitatory postsynaptic scaffolding proteins PSD95, SAP102, compared to wild type
Exp Paradigm: Western blot
 Western blot
 Unreported
Targeted protein expression1
Decreased
Description: Decreased expression of NL3 protein
Exp Paradigm: Western blot
 Western blot
 3 months
Anxiety1
 No Change
 Elevated plus maze test
 2-4 months
Anxiety1
 No Change
 Open field test
 2-4 months
Exploratory activity1
 No Change
 Novel object interaction test
 2-4 months
Gene expression1
 No Change
 Quantitative PCR (qRT-PCR)
 3 months
Protein expression level evidence2
 No Change
 Western blot
 Unreported
Protein expression level evidence2
 No Change
 Western blot
 Unreported
Protein expression level evidence3
 No Change
 Peak-scaled non-stationary fluctuation analysis
 Unreported
Protein expression level evidence1
 No Change
 Western blot
 3 months
General locomotor activity1
 No Change
 Light-dark exploration test
 2-4 months
Motor coordination and balance1
 No Change
 Accelerating rotarod test
 2-4 months
Brain morphology1
 No Change
 Immunohistochemistry; Fluorescence microscopy
 3 months
Brain morphology1
 No Change
 Electron microscopy
 8 weeks
Synapse density2
 No Change
 Fluorescence microscopy
 Unreported
Synapse density: Excitatory1
 No Change
 Immunohistochemistry; Fluorescence microscopy
 3 months
Synaptic morphology2
 No Change
 Electron microscopy
 Unreported
Membrane potential3
 No Change
 Whole-cell patch clamp
 P4-P9
Neuronal ion channel activity3
 No Change
 Whole-cell patch clamp
 P11-P15
Neurotransporter activity3
 No Change
 Whole-cell patch clamp
 P11-P16
Paired-pulse facilitation2
 No Change
 Field potential recordings; Paired-pulse facilitation
 Unreported
Spontaneous post synaptic events: excitatory currents2
 No Change
 Whole-cell patch clamp
 Unreported
Spontaneous post synaptic events: excitatory currents1
 No Change
 Whole-cell patch clamp
 Unreported
Spontaneous post synaptic events: excitatory currents3
 No Change
 Whole-cell patch clamp
 P11-P15
Spontaneous post synaptic events: excitatory currents3
 No Change
 Whole-cell patch clamp
 P4-P9
Spontaneous post synaptic events: inhibitory currents2
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic neuroreceptor ratio (NMDAR/AMPAR) dependent transmission3
 No Change
 Whole-cell patch clamp
 P4-P9
Synaptic neuroreceptor ratio (NMDAR/AMPAR) dependent transmission2
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic plasticity1
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic transmission: excitatory1
 No Change
 Whole-cell patch clamp
 Unreported
Tonic currents through extrasynaptic receptors3
 No Change
 Whole-cell patch clamp
 P11-P15
Voltage sensitivity of N-methyl D-aspartate (NMDA) receptors2
 No Change
 Whole-cell patch clamp
 Unreported
Vision1
 No Change
 Morris water maze test: visible platform test
 2-4 months
Inanimate object preference2
 No Change
 Novel object interaction test
 Unreported
Social approach2
 No Change
 Three-chamber social approach test: sociability
 Unreported
 Not Reported:

NLGN3_2_KO

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor coordination and balance2
Increased
Description: Normal initial coordination with increased learning rate, compared to male littermate controls
Exp Paradigm: Accelerating rotarod, nine trials 4 to 40 rpm in 300 s
 Accelerating rotarod test
 6 weeks
Spontaneous post synaptic events: inhibitory currents3
Increased
Description: Increased frequency of spontaneous mIPSCs in hippocampus, compared to wild type
Exp Paradigm: Whole cell patch-clamp recordings
 Whole-cell patch clamp
 Unreported
Spontaneous post synaptic events: excitatory currents3
Decreased
Description: Decreased frequency of spontaneous mEPSCs in hippocampus, compared to wild type
Exp Paradigm: Whole cell patch-clamp recordings
 Whole-cell patch clamp
 Unreported
Protein expression level evidence1
Decreased
Description: Decreased expression of NL1 protein
Exp Paradigm: Western blot
 Western blot
 3 months
Targeted protein expression1
Decreased
Description: Loss of expression of NL3 protein
Exp Paradigm: Western blot
 Western blot
 3 months
General characteristics1
 No Change
 General observations
 Unreported
Protein expression level evidence1
 No Change
 Western blot
 3 months
Protein expression level evidence1
 No Change
 Western blot
 3 months
Synapse density: Excitatory1
 No Change
 Immunohistochemistry; Fluorescence microscopy
 3 months
Synapse density: Inhibitory1
 No Change
 Immunohistochemistry; Fluorescence microscopy
 3 months
Paired-pulse facilitation3
 No Change
 Field potential recordings; Paired-pulse facilitation
 Unreported
Spontaneous post synaptic events: excitatory currents1
 No Change
 Whole-cell patch clamp
 Unreported
Spontaneous post synaptic events: inhibitory currents1
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic neuroreceptor ratio (NMDAR/AMPAR) dependent transmission3
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic neuroreceptor ratio (NMDAR/AMPAR) dependent transmission3
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic plasticity1
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic plasticity: hippocampal LTP3
 No Change
 Field potential recordings; Long term potentiation (LTP)
 Unreported
Synaptic transmission: excitatory3
 No Change
 Field potential recordings: slope of EPSP by range of stimulus (input/ output relationship)
 Unreported
Synaptic transmission: excitatory1
 No Change
 Whole-cell patch clamp
 Unreported
Synaptic transmission: inhibitory1
 No Change
 Whole-cell patch clamp
 Unreported
 Not Reported:

NLGN3_4_KO

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity1
Increased
Description: Increased total distance traveled, mean velocity, compared to wild type
Exp Paradigm: Elevated plus maze test
 Elevated plus maze test
 12-15 weeks
Hyperactivity1
Increased
Description: Increased total distance traveled, mean velocity, compared to wild type
Exp Paradigm: Open field test, mice were not nave
 Open field test
 12-15 weeks
Brain size1
Decreased
Description: Decreased volume of brain, excluding olfactory bulb, cerebellum and brainstem
Exp Paradigm: Magnetic resonance imaging
 Magnetic resonance imaging (MRI)
 12-15 weeks
Olfaction1
Decreased
Description: Decreased response, measured by increased latency in food finding, compared to wild type
Exp Paradigm: Buried food test with no cues, mice were not nave
 Buried food test
 12-15 weeks
Social memory1
Decreased
Description: Decreased preference for novel social target, compared to wild type
Exp Paradigm: Three-chamber social approach test: social novelty, mice were not nave
 Three-chamber social approach test: social novelty
 12-15 weeks
Ultrasonic vocalization1
Decreased
Description: Decreased response, measured by increased latency to initiate ultrasonic vocalizations in respose to female in estrous and decreased number of calls
Exp Paradigm: Call latency towards an unfamiliar female mouse in estrous, mice were not nave
 Monitoring ultrasonic vocalizations: reciprocal social interaction test: male-female
 12-15 weeks
Exploratory activity1
Increased
Description: Increased number of holes explored in hole-board test
Exp Paradigm: Hole-board test, mice were not nave
 Hole-board test
 12-15 weeks
Cued or contextual fear conditioning: Memory of context1
Decreased
Description: Decreased memory, measured by decreased freezing time in response to context, compared to wild type
Exp Paradigm: Fear conditioning test: contextual
 Fear conditioning test: contextual
 12-15 weeks
Cognitive flexibility1
Increased
Description: Increased cognitive flexibility measured by decreased latency to reach hidden platform in new location on first trial, but No Change in learning rate of new location, and No Change in time spent in new target quadrant in probe trial after learning, compared to wild type
Exp Paradigm: Morris water maze test: reversal learning, 8 trials, mice were not nave
 Morris water maze test: reversal learning
 12-15 weeks
Cued or contextual fear conditioning: Memory of cue1
Decreased
Description: Decreased memory, measured by decreased freezing time in response to acoustic cue, compared to wild type
Exp Paradigm: Fear conditioning test: acoustic cue-dependent
 Fear conditioning test: acoustic cue-dependent
 12-15 weeks
Size/growth1
 No Change
 General observations
 12-15 weeks
Anxiety1
 No Change
 Elevated plus maze test
 12-15 weeks
Anxiety1
 No Change
 Open field test
 12-15 weeks
Spatial learning1
 No Change
 Morris water maze test: hidden platform trial
 12-15 weeks
Spatial learning1
 No Change
 Morris water maze test: visible platform trial
 12-15 weeks
Spatial reference memory1
 No Change
 Morris water maze test: probe trial
 12-15 weeks
Motor coordination and balance1
 No Change
 Accelerating rotarod test
 12-15 weeks
Sensorimotor gating1
 No Change
 Prepulse inhibition
 12-15 weeks
Taste1
 No Change
 Sucrose preference test
 12-15 weeks
Social approach1
 No Change
 Three-chamber social approach test: sociability
 12-15 weeks
Social interaction1
 No Change
 Reciprocal social interaction test
 12-15 weeks
 Not Reported:

NLGN3_3_KI_R451C

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Gait1
Abnormal
Description: Increased forepaw width, but No Change in hindpaw width or stride length in NL3 females compared to wild types
Exp Paradigm: Footprint pattern analysis
 Footprint analysis
 Adult
Grip strength1
Decreased
Description: Shorter latency to fall in the wire hang test for NL3 males compared to wild types
Exp Paradigm: Wire hang test
 Wire hang test
 Adult
Righting response1
Decreased
Description: Delayed righting response in males and females
Exp Paradigm: Righting response test
 Righting reflex test
 Postnatal day 2-6
General locomotor activity1
Decreased
Description: Decreased rate of rearing (vertical) activity in NL3 male mice compared to wild types
Exp Paradigm: Open field test
 Open field test
 Adult
Motor coordination and balance1
Increased
Description: Increased latency to fall in male NL3 mice
Exp Paradigm: Accelerating rota rod test
 Accelerating rotarod test
 Adult
Synaptic transmission: excitatory2
Increased
Description: Increased fEPSP, compared to wild type
Exp Paradigm: Field potential recordings: slope of EPSP by range of stimulus (input/ output relationship)
 Field potential recordings: slope of EPSP by range of stimulus (input/ output relationship)
 Unreported
Acoustic startle reflex1
Decreased
Description: Decreased startle response to 100-dB, 110-dB and 120-dB acoustic stimuli
Exp Paradigm: Acoustic startle
 Prepulse inhibition
 Adult
Social scent marking or recognition1
Increased
Description: Shorter latency to reach nest area, NL3 females compared to wild types
Exp Paradigm: Homing test
 Homing test
 Postnatal day 9, Females
Ultrasonic vocalization1
Decreased
Description: Decreased ultrasonic vocalization calls in male pups, but No Change in duration, peak frequency or amplitude of calls, compared to wild types
Exp Paradigm: Maternal separation
 Monitoring ultrasonic vocalizations: maternal separation
 Postnatal day 8
Size/growth1
Decreased
Description: Decreased body weight in NL3 females, compared to wild types
Exp Paradigm: General observations
 General observations
 Adult
Size/growth1
Decreased
Description: Decreased body weight in female NL3 pups, compared to wild type
Exp Paradigm: General observations
 General observations
 Postnatal day 6 to 12
Size/growth1
Increased
Description: Increased body weight in male NL3 pups, compared to wild type
Exp Paradigm: General observations
 General observations
 Postnatal day 6 to 11
Ultrasonic vocalization1
 No Change
 Monitoring ultrasonic vocalizations: maternal separation
 Postnatal day 2 to 11
Size/growth1
 No Change
 General observations
 Adult
Anxiety1
 No Change
 Elevated plus maze test
 Adult
Cognitive flexibility1
 No Change
 Morris water maze test: reversal learning
 Adult
Cued or contextual fear conditioning1
 No Change
 Fear conditioning test: contextual and acoustic cue-dependent
 Adult
Spatial learning1
 No Change
 Morris water maze test: hidden platform trial
 Adult
Spatial reference memory1
 No Change
 Morris water maze test: probe trial
 Adult
Gait1
 No Change
 Footprint analysis
 Adult
General locomotor activity1
 No Change
 Open field test
 Adult
General locomotor activity: Ambulatory activity1
 No Change
 Open field test
 Adult
Motor coordination and balance1
 No Change
 Accelerating rotarod test
 Adult
Hearing1
 No Change
 Prepulse inhibition
 Adult
Sensorimotor gating1
 No Change
 Prepulse inhibition
 Adult
Social approach1
 No Change
 Three-chamber social approach test
 Adult
Social interaction1
 No Change
 Reciprocal social interaction test: juvenile play
 Posnatal day 19 to 23
Social scent marking or recognition1
 No Change
 Homing test
 Postnatal day 9, Females
 Not Reported:

NLGN3_10_cKO_D1-Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor coordination and balance1
Increased
Description: Normal initial coordination with increased learning rate, compared to NL3-cKO littermate controls
Exp Paradigm: Accelerating rotarod, six trials 4 to 40 rpm in 300 s, six more trials 8 to 80 rpm in 300 s
 Accelerating rotarod test
 6 weeks
Hyperactivity1
Increased
Description: Increased total distance traveled and increased number of ambulatory episodes, compared to NL3-cKO littermate controls
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
 Not Reported:

NLGN3_11_cKO_A2a-Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity1
 No Change
 Open field test
 6 weeks
Motor coordination and balance1
 No Change
 Accelerating rotarod test
 6 weeks
 Not Reported:

NLGN3_12_KI_R451C_D1-Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor coordination and balance1
Increased
Description: Normal initial coordination with increased learning rate, compared to NL3-cKO littermate controls
Exp Paradigm: Accelerating rotarod, six trials 4 to 40 rpm in 300 s, six more trials 8 to 80 rpm in 300 s
 Accelerating rotarod test
 6 weeks
 Not Reported:

NLGN3_13_cKO_DS_Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity1
 No Change
 Open field test
 6 weeks
Motor coordination and balance1
 No Change
 Accelerating rotarod test
 6 weeks
 Not Reported:

NLGN3_14_cKO_NAc_Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor coordination and balance1
Increased
Description: Normal initial coordination with increased learning rate, compared to NL3-cKO littermate controls injected with catalytically inactive Cre
Exp Paradigm: Accelerating rotarod, six trials 4 to 40 rpm in 300 s, six more trials 8 to 80 rpm in 300 s
 Accelerating rotarod test
 6 weeks
Hyperactivity1
Increased
Description: Increased total distance traveled and increased number of ambulatory episodes, compared to NL3-cKO littermate controls injected with catalytically inactive Cre
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
 Not Reported:

NLGN3_5_KO

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity1
Increased
Description: Increased total distance traveled and increased number of ambulatory episodes, compared to male littermate controls, No Change in speed
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
Motor coordination and balance1
Increased
Description: Normal initial coordination with increased learning rate, compared to male littermate controls
Exp Paradigm: Accelerating rotarod, six trials 4 to 40 rpm in 300 s, six more trials 8 to 80 rpm in 300 s
 Accelerating rotarod test
 6 weeks
Perseveration1
Increased
Description: Increased repetitive behavior with training by observed reduction of variability of vertical location of each step, step length and time between steps, compared to male littermate controls
Exp Paradigm: Accelerating rotarod, first 30 s of trial 7 and trial 12 (8 to 80 rpm)
 Accelerating rotarod test
 6 weeks
Stereotypy1
Increased
Description: Increased time spent ambulatory and performing stereotypic movements, increased number of wall jumps and abnormal bias in the direction of rotation during locomotion
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
Stereotypy1
Increased
Description: Increased force variance during periods of low mobility
Exp Paradigm: Force plate actometer assay, 25-minute sessions at similar time of day
 Force plate actometer test
 6 weeks
Anxiety1
 No Change
 Open field test
 6 weeks
 Not Reported:

NLGN3_6_KI_R451C

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor coordination and balance1
Increased
Description: Normal initial coordination with increased learning rate, compared to male littermate controls
Exp Paradigm: Accelerating rotarod, six trials 4 to 40 rpm in 300 s, six more trials 8 to 80 rpm in 300 s
 Accelerating rotarod test
 6 weeks
Hyperactivity1
Increased
Description: Increased total distance traveled and increased number of ambulatory episodes, compared to male littermate controls, No Change in speed
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
Stereotypy1
Increased
Description: Increased time spent ambulatory and performing stereotypic movements
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
Perseveration1
Increased
Description: Increased repetitive behavior with training by observed reduction of variability of vertical location of each step, step length and time between steps, compared to male littermate controls
Exp Paradigm: Accelerating rotarod, first 30 s of trial 7 and trial 12 (8 to 80 rpm)
 Accelerating rotarod test
 6 weeks
Anxiety1
 No Change
 Open field test
 6 weeks
 Not Reported:

NLGN3_7_cKO_Nestin-Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity1
Increased
Description: Increased total distance traveled and increased number of ambulatory episodes, compared to NL3-cKO littermate controls
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
Gene expression1
Decreased
Description: Complete loss of Nlgn3 mRNA in whole brain, compared to NL3-cKO littermate controls
Exp Paradigm: Quantitative PCR (qRT-PCR)
 Quantitative PCR (qRT-PCR)
 4 weeks
Targeted protein expression1
Decreased
Description: Complete loss of NL3 protein in whole brain, compared to NL3-cKO littermate controls
Exp Paradigm: Western blot
 Western blot
 4 weeks
Gene expression1
 No Change
 Quantitative PCR (qRT-PCR)
 4 weeks
 Not Reported:

NLGN3_8_cKO_L7-Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity1
Increased
Description: Increased total distance traveled and increased number of ambulatory episodes, compared to NL3-cKO littermate controls
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
Motor coordination and balance1
 No Change
 Accelerating rotarod test
 6 weeks
 Not Reported:

NLGN3_9_cKO_PV-Cre

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hypoactivity1
Increased
Description: Decreased total distance traveled and no significant change in number of ambulatory episodes, compared to NL3-cKO littermate controls
Exp Paradigm: Open field test, illuminated 60-minute session
 Open field test
 6 weeks
Motor coordination and balance1
 No Change
 Accelerating rotarod test
 6 weeks
 Not Reported:

NLGN3_1_KI_R451C_GEPH-GFP

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Dendritic spine density and architecture: turnover rate1
Increased
Description: Nlgn3R451C mice show increased turnover of Gephyrin-negative puncta associated spines in the SSC compared to wild type mice
Exp Paradigm: Turnover of Gephyrin-GFP negative puncta-associated spines was measured
 Two-photon microscopy: in vivo over two days, somatosensory cortex
 P21-23
Neuronal activation following behavioral stimulation: c-Fos levels1
Decreased
Description: Nlgn3R451C mice have reduced density of C-Fos positive cells in the barrel cortex region corresponding to row C of whiskers, in layers 2/3 compared to wild type mice
Exp Paradigm: All whiskers except row C were removed and mice exposed to enriched environment for 1 h before sacrifice
 Immunohistochemistry: density of c-Fos positive cells in layer 2/3 of barrel cortex
 P21-23
Dendritic spine density and architecture1
 No change
 Two-photon microscopy: in vivo over two days, somatosensory cortex
 P21-23
Dendritic spine density and architecture: turnover rate1
 No change
 
 P21-23
Synapse density: Excitatory1
 No change
 Two-photon microscopy: in vivo over two days, somatosensory cortex
 P21-23
Neuronal activation following behavioral stimulation: c-Fos levels1
 No change
 Immunohistochemistry: density of c-Fos positive cells in layer 4 of barrel cortex
 P21-23
 Not Reported:

NLGN3_1_KI_R451C_PSD95-GFP

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Dendritic spine density and architecture: turnover rate1
Increased
Description: Nlgn3R451C mice show increased turnover of PSD95-positive puncta associated spines in the AFC compared to wild type mice
Exp Paradigm: Turnover of PSD-95 -GFP positive puncta of spines was measured
 Two-photon microscopy: in vivo over two days, anterior frontal cortex
 P21-23
Dendritic spine density and architecture1
 No change
 Two-photon microscopy: in vivo over two days, anterior frontal cortex
 P21-23
Dendritic spine density and architecture: turnover rate1
 No Change
 Two-photon microscopy: in vivo over two days, anterior frontal cortex
 P21-23
Synapse density: Excitatory1
 No Change
 Two-photon microscopy: in vivo over two days, anterior frontal cortex
 P21-23
 Not Reported:


Interactor Symbol Interactor Name Interactor Organism Entrez ID Uniprot ID Interaction Type Evidence Reference
AES amino-terminal enhancer of split 166 Q08117 Y2H
Sakai Y 2011
AKT1 v-akt murine thymoma viral oncogene homolog 1 207 P31749 Y2H
Sakai Y 2011
ALPP CBS 250 P05187 Y2H
Shen C 2015
AP2A2 adaptor-related protein complex 2, alpha 2 subunit 161 O94973 Y2H
Shen C 2015
APC2 adenomatosis polyposis coli 2 10297 O95996 Y2H
Sakai Y 2011
ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) 468 P18848 Y2H
Shen C 2015
ATXN1 ataxin 1 6310 P54253 Y2H
Sakai Y 2011
C1orf122 chromosome 1 open reading frame 122 127687 E9PQ13 Y2H
Shen C 2015
C1QA Complement C1q subcomponent subunit A 712 P02745 Y2H
Shen C 2015
CCAR2 Cell cycle and apoptosis regulator protein 2 57805 Q8N163 Y2H
Shen C 2015
CGB chorionic gonadotropin, beta polypeptide 1082 P01233 Y2H
Shen C 2015
COBL cordon-bleu homolog (mouse) 23242 O75128 Y2H
Sakai Y 2011
CTSD cathepsin D 1509 P07339 Y2H
Shen C 2015
CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 1583 P05108 Y2H;IP/WB;Immunofluorescence
Shen C 2015
DPEP2 Dipeptidase 2 64174 Q9H4A9 Y2H
Shen C 2015
EBPL Emopamil-binding protein-like 84650 Q9BY08 Y2H
Shen C 2015
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 1915 P68104 Y2H;IP/WB;Immunofluorescence
Shen C 2015
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 2202 Q12805 Y2H
Sakai Y 2011
EFS embryonal Fyn-associated substrate 10278 O43281 Y2H
Shen C 2015
FANCG Fanconi anemia, complementation group G 2189 O15287 Y2H
Shen C 2015
FBLN1 fibulin 1 2192 P23142 Y2H
Shen C 2015
FHOD1 formin homology 2 domain containing 1 29109 Q9Y613 Y2H
Shen C 2015
FKBP1A FK506 binding protein 1A, 12kDa 2280 P62942 Y2H
Shen C 2015
FLNA filamin A, alpha 2316 P21333 Y2H;IP/WB;Immunofluorescence
Shen C 2015
GDF15 Growth/differentiation factor 15 9518 Q99988 Y2H
Shen C 2015
GPR175 Transmembrane protein adipocyte-associated 1 131601 Q86W33 Y2H;IP/WB;Immunofluorescence
Shen C 2015
GUK1 guanylate kinase 1 2987 Q16774 Y2H
Shen C 2015
HID1 Protein HID1 283987 Q8IV36 Y2H
Shen C 2015
HIVEP1 human immunodeficiency virus type I enhancer binding protein 1 3096 P15822 Y2H
Sakai Y 2011
ITPRIP inositol 1,4,5-trisphosphate receptor interacting protein 85450 Q8IWB1 Y2H;IP/WB;Immunofluorescence
Shen C 2015
LGALS1 Galectin-1 3956 P09382 Y2H
Shen C 2015
MAN2C1 Alpha-mannosidase 2C1 4123 Q9NTJ4 Y2H
Shen C 2015
MAP1S microtubule-associated protein 1S 55201 Q66K74 Y2H
Shen C 2015
MEOX2 Homeobox protein MOX-2 4223 P50222 Y2H
Corominas R 2014
MIEN1 Migration and invasion enhancer 1 84299 Q9BRT3 Y2H
Shen C 2015
MT-CO2 Cytochrome c oxidase subunit 2 4513 P00403 Y2H;IP/WB;Immunofluorescence
Shen C 2015
NFATC4 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 4776 Q14934 Y2H
Shen C 2015
NRD1 nardilysin (N-arginine dibasic convertase) 4898 O43847 Y2H
Shen C 2015
OAZ1 ornithine decarboxylase antizyme 1 4946 P54368 Y2H
Shen C 2015
OR1F12 olfactory receptor, family 1, subfamily F, member 12 442179 Q8NHA8 Y2H
Shen C 2015
PICK1 protein interacting with PRKCA 1 9463 Q9NRD5 Y2H
Sakai Y 2011
PKIB cAMP-dependent protein kinase inhibitor beta 5570 Q9C010 Y2H
Shen C 2015
PLB1 Phospholipase B1, membrane-associated 151056 Q6P1J6 Y2H
Shen C 2015
PLC4 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 5332 Q15147 Y2H
Shen C 2015
PSAP prosaposin 5660 P07602 Y2H
Shen C 2015
PSG1 Pregnancy-specific beta-1-glycoprotein 1 5669 P11464 Y2H
Shen C 2015
PSG11 pregnancy specific beta-1-glycoprotein 11 5680 Q9UQ72 Y2H
Shen C 2015
PSG3 Pregnancy-specific beta-1-glycoprotein 3 5671 Q16557 Y2H
Shen C 2015
PSG4 pregnancy specific beta-1-glycoprotein 4 5672 Q00888 Y2H
Shen C 2015
PSG5 Pregnancy-specific beta-1-glycoprotein 5 5673 Q15238 Y2H
Shen C 2015
QARS glutaminyl-tRNA synthetase 5859 P47897 Y2H
Shen C 2015
QPRT Nicotinate-nucleotide pyrophosphorylase [carboxylating] 23475 Q15274 Y2H;IP/WB;Immunofluorescence
Shen C 2015
RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1 54715 Q9NWB1 in silico target prediction; Splicing microarray
Zhang C 2008
RBM9 RNA binding protein fox-1 homolog 2 9606 O43251 Y2H
Sakai Y 2011
SNTG2 syntrophin, gamma 2 54221 Q9NY99 IP
Yamakawa H 2007
SPAG5 sperm associated antigen 5 10615 Q96R06 Y2H
Shen C 2015
SPINT1 Kunitz-type protease inhibitor 1 6692 O43278 Y2H
Shen C 2015
SSR4 signal sequence receptor, delta 6748 P51571 Y2H
Shen C 2015
TDRD7 tudor domain containing 7 23424 Q8NHU6 Y2H
Sakai Y 2011
TNNT3 Troponin T, fast skeletal muscle 7140 P45378 Y2H
Shen C 2015
TRIM33 tripartite motif containing 33 51592 B3KN30 Y2H
Shen C 2015
TXNIP thioredoxin interacting protein 10628 Q9H3M7 Y2H
Shen C 2015
UBXN6 UBX domain protein 6 80700 Q9BZV1 Y2H
Shen C 2015
UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial 7384 P31930 Y2H
Shen C 2015
FMR1 fragile X mental retardation 1 14265 P35922 HITS-CLIP
Darnell JC 2011
Nlgn1 neuroligin 1 192167 Q99K10 IP/WB
Budreck EC 2007
Nlgn2 neuroligin 2 216856 Q69ZK9 IP/WB
Budreck EC 2007
Dlg2 discs, large homolog 2 (Drosophila) 64053 Q63622 Y2H
Irie M 1997
Dlg3 discs, large homolog 3 (Drosophila) 58948 Q62936 Y2H
Irie M 1997
Dlg4 discs, large homolog 4 (Drosophila) 29495 P31016 Y2H; Affinity chromatography
Irie M 1997
Nrxn1 neurexin 1 60391 Q63373 IP/WB
Ichtchenko K 1996
Nrxn2 neurexin 2 116595 Q63376 IP/WB
Ichtchenko K 1996
Nrxn3 neurexin 3 116508 Q07310 IP/WB
Ichtchenko K 1996
Rapgef4 Rap guanine nucleotide exchange factor (GEF) 4 252857 Q9Z1C7 IP/WB
Woolfrey KM 2009

HELP